FDA
-
-
-
-
-
-
-
Amarin highlights guideline support for icosapent ethyl in heart risk care
-
-
-
-
-
-
-
This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease
-
-
-
-
-
-
-
Amarin Corporation (AMRN) PT Raised to $12 at Leerink Partners
-
-
-
-
-
-
-
New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in C
-
-
-
-
-
-
-
Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist
-
-
-
-
-
-
-
Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (
-
-
-
-
-
-
-
Amarin Corp. (AMRN) Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction
-
325,516 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

